Dayvigo Re-Titration After Stopping: How to Restart Lemborexant Safely

What Does Re-Titration Mean for Dayvigo?

Re-titration means restarting lemborexant from its lowest approved dose rather than returning directly to the dose you were taking before you stopped. The FDA prescribing information for Dayvigo does not describe a separate re-titration protocol distinct from initial titration. In practice, that means the same two-step schedule applies whether you are brand new to the drug or coming back after a gap.

You take 5 mg at bedtime on night one. You stay there long enough to confirm you tolerate it before moving to 10 mg. The prescribing information lists 5 mg as the recommended starting dose for all adults and 10 mg as the maximum, with the explicit note that the lower dose may be sufficient for some patients and should be tried first.

The clinical logic behind restarting low is straightforward. A pause of weeks or months resets your CNS adaptation to the drug, so you may be more sensitive to next-day sedation or psychomotor effects than you were after months of steady use.

Why You Might Have Stopped in the First Place

Before restarting, your provider will want to understand the reason you discontinued. Common reasons include:

• Residual next-day sleepiness that interfered with driving or work
• A planned pregnancy or confirmed pregnancy
• Surgery requiring general anesthesia
• A decision to try non-drug options such as cognitive behavioral therapy for insomnia (CBT-I)
• Financial or insurance interruption

The reason matters because it shapes whether re-titration is appropriate at all, and whether any dose adjustment is warranted from the start.

What the FDA Label Actually Says

The Dayvigo FDA prescribing information states: take 5 mg no more than once per night, immediately before bed, with at least 7 hours remaining before planned awakening. The dose may be increased to 10 mg if 5 mg is tolerated but not effective. No dose titration schedule with specific night-by-night instructions appears in the label, which is consistent with other drugs in the dual orexin receptor antagonist (DORA) class.

How to Titrate Dayvigo: The Step-by-Step Approach

The approved titration is two steps. Simple, but the timing between steps is where clinical judgment enters.

Step 1: 5 mg at Bedtime

Take one 5 mg tablet orally within 30 minutes of going to bed, only when you have at least 7 hours before you need to wake up. Do not take it with or right after a high-fat meal. The SUNRISE-1 trial demonstrated that a high-fat meal delays the time to maximum plasma concentration (Tmax) from approximately 1 hour to 3 hours, which blunts sleep-onset effects.

You should stay at 5 mg for at least 7 nights, and preferably two full weeks, before deciding whether it is working. Sleep architecture changes are not always obvious in the first few nights because the brain is adjusting.

Step 2: Escalation to 10 mg

If 5 mg does not produce meaningful improvement in sleep onset or sleep maintenance after a fair trial, and if you are not experiencing excessive next-day sedation, your clinician may increase the dose to 10 mg. The SUNRISE-1 randomized controlled trial, which enrolled 291 adults and compared lemborexant 5 mg and 10 mg against placebo over 30 nights, found that both doses significantly reduced subjective sleep onset latency compared with placebo, and the 10 mg dose produced larger reductions in wake after sleep onset (WASO).

Specifically, lemborexant 10 mg reduced subjective WASO by a mean of approximately 30 minutes versus placebo at month 1 in SUNRISE-1, compared with roughly 20 minutes for the 5 mg arm.

How Quickly Can You Increase Dayvigo?

The FDA label does not set a mandatory minimum interval before escalation. Clinical practice guidelines from the American Academy of Sleep Medicine do not specify a number of nights either. A reasonable clinical threshold is 7 to 14 nights at 5 mg, giving you enough consecutive nights to distinguish true inadequate response from first-week adjustment effects.

Increasing faster than 7 nights is generally inadvisable because next-day sedation risk is highest in the first week and may underestimate the steady-state burden you would carry at 10 mg.

Women-Specific Pharmacokinetics: Why Your Dose Timing May Need to Differ

Sex differences in how your body handles lemborexant are clinically meaningful, not a footnote.

Body Composition and Drug Exposure

Lemborexant is highly lipophilic and extensively distributed into adipose tissue. Women typically carry a higher percentage of body fat relative to total body weight than men of comparable size, which can extend the drug's volume of distribution and prolong its elimination half-life. The mean half-life of lemborexant in clinical pharmacology studies is approximately 17 to 19 hours. In women with lower lean body mass, plasma concentrations may remain higher into the next morning, raising the risk of residual sedation.

The FDA prescribing information notes that exposure (AUC) in women is approximately 30 percent higher than in men after the same oral dose. This is a direct pharmacokinetic sex difference, not a theoretical concern.

Menstrual Cycle Considerations

No published trial has formally mapped lemborexant plasma levels across the menstrual cycle. Progesterone, which rises in the luteal phase, has mild sedative properties of its own through GABA-A modulation. Women with premenstrual dysphoric disorder (PMDD) or severe premenstrual syndrome may notice that the drug's sedation profile feels different in the week before menstruation than in the follicular phase. This has not been studied directly. If you notice marked variation in next-day grogginess across your cycle, reporting it to your provider is worthwhile.

Perimenopause and Postmenopause: A Critical Life Stage

Insomnia is among the most common and undertreated symptoms of perimenopause. The Menopause Society recognizes insomnia as a core menopausal symptom, separate from night sweats, and notes that it frequently persists even after vasomotor symptoms resolve.

Perimenopausal and postmenopausal women face two compounding pharmacokinetic changes. First, declining estrogen alters hepatic CYP3A4 activity, which is the primary enzyme responsible for lemborexant metabolism. Second, the proportion of body fat rises with menopause, further extending the drug's distribution. Both shifts push toward higher effective drug exposure. This means a postmenopausal woman re-titrating Dayvigo may have a stronger case for staying at 5 mg long-term rather than escalating to 10 mg, compared with a 30-year-old premenopausal woman of similar weight.

Women starting lemborexant in perimenopause who are also taking hormone therapy (HT) should note that estradiol and progestin formulations are not listed as clinically significant CYP3A4 inhibitors at standard therapeutic doses, so no dose adjustment is required based on HT use alone. Still, oral micronized progesterone (Prometrium), which itself has CNS sedative effects, may add to next-day drowsiness when combined with 10 mg lemborexant. Clinicians should ask directly about progesterone formulation when co-prescribing.

PCOS, Hormonal Acne, and Insomnia: An Often-Missed Connection

Women with polycystic ovary syndrome (PCOS) have a documented higher prevalence of sleep-disordered breathing, including obstructive sleep apnea (OSA), compared with age-matched controls, with some studies estimating a prevalence of 35 to 80 percent in women with PCOS. Lemborexant, like all sedative-hypnotics, is contraindicated or requires extreme caution in patients with moderate to severe OSA because respiratory drive suppression during sleep can worsen apneic episodes.

If you have PCOS and insomnia and have not had a formal sleep study, that assessment should precede or accompany a decision to restart Dayvigo. The sedating effect of a DORA on upper-airway muscle tone is a real physiological concern, not an abstract precaution.

Pregnancy, Lactation, and Contraception

Dayvigo is not recommended during pregnancy. This is a required section for any drug-related article on WomanRx, and the safety picture here is genuinely limited.

Pregnancy

The FDA label assigns no formal letter category (the old A/B/C/D/X system was retired for drugs approved after 2015), but the Dayvigo prescribing information states clearly that there are no adequate and well-controlled studies in pregnant women. Animal reproductive toxicology studies showed developmental toxicity at exposures above those achieved at the maximum recommended human dose. Specifically, rat studies at 60 times the 10 mg human equivalent showed reduced fetal body weight and delayed skeletal ossification.

Because sleep architecture changes profoundly during pregnancy, particularly in the third trimester where insomnia affects an estimated 75 to 84 percent of pregnant women, the temptation to restart a previously effective sleep aid is understandable. The risk-benefit conversation must be had with a maternal-fetal medicine specialist or your OB-GYN, not made unilaterally. CBT-I remains the first-line recommendation for insomnia during pregnancy.

If you are of reproductive age and sexually active, you do not need a specific contraceptive requirement to take lemborexant (it is not a teratogen in the category of isotretinoin or thalidomide), but given the absence of human safety data, a reliable contraceptive method is a sensible precaution if you choose to use Dayvigo at maximum dose over extended periods.

Lactation

The FDA label states that there are no data on the presence of lemborexant in human breast milk, the effects on the breastfed infant, or the effects on milk production. Animal studies showed lemborexant present in rat milk at low levels. Given the drug's high lipophilicity and long half-life (17 to 19 hours), transfer to breast milk is pharmacologically plausible even if unquantified.

The recommendation from the WomanRx clinical team is to avoid lemborexant while breastfeeding. If postpartum insomnia is severe, CBT-I and short-term use of low-dose doxylamine (which has more established lactation data) should be discussed with your provider before restarting Dayvigo.

Postpartum Re-Titration

If you stopped Dayvigo because you were trying to conceive, became pregnant, or were breastfeeding, restarting after lactation ends is a conversation worth having at your six-week postpartum visit or your first well-woman exam after weaning. Sleep deprivation in postpartum women is multifactorial, and a full sleep assessment, including ruling out postpartum depression and postpartum thyroiditis, should precede restarting any hypnotic.

Who This Is Right For and Who Should Think Twice

Good Candidates for Re-Titration

• Women who previously tolerated lemborexant well at 5 mg or 10 mg and stopped for a non-safety reason (cost, surgery, planned pregnancy)
• Perimenopausal women with confirmed chronic insomnia who have completed or declined a CBT-I program
• Women with insomnia whose sleep difficulty is primarily sleep-maintenance type (waking in the middle of the night), since SUNRISE-1 showed particularly strong WASO reductions
• Women who previously experienced next-day sedation only at 10 mg and are willing to stay at 5 mg long-term

Situations That Warrant Pause or a Different Approach

• Active pregnancy or breastfeeding (see above)
• Newly diagnosed or untreated obstructive sleep apnea, particularly relevant in women with PCOS or post-menopausal women where OSA is underdiagnosed
• Concurrent use of strong CYP3A4 inhibitors (fluconazole, clarithromycin, some HIV antiretrovirals), which can increase lemborexant AUC substantially. The FDA label recommends the dose not exceed 5 mg when co-administered with moderate CYP3A4 inhibitors, and the drug should be avoided with strong inhibitors
• Severe hepatic impairment: dose is capped at 5 mg
• A history of stopping Dayvigo because of complex sleep behaviors (sleepwalking, sleep driving), which are class-wide warnings for all sedative-hypnotics per FDA guidance

What Real-World Use Tells Us That Trials Don't

The SUNRISE-1 trial ran 30 nights. SUNRISE-2, the longer phase 3 trial published in Sleep Medicine, extended follow-up to 12 months and showed sustained efficacy without significant tolerance development at either dose. Neither trial had a formal re-titration arm because participants were not asked to stop and restart.

What post-marketing clinical experience and the WomanRx clinical team's review of the pharmacokinetic data suggest is a practical re-titration framework that does not appear in any published guideline:

The WomanRx Re-Titration Framework for Lemborexant

| Gap Since Stopping | Suggested Restart Strategy | Rationale | |---|---|---| | <2 weeks | Resume prior dose with caution | CNS adaptation likely still present; confirm original indication still applies | | 2 to 8 weeks | Restart at 5 mg, assess after 7 nights | Partial CNS reset; escalate only if clearly subtherapeutic | | >8 weeks or any pregnancy/lactation gap | Full restart at 5 mg, 14-night observation before considering escalation | Full pharmacological reset; higher sensitivity to sedation likely | | Any gap with new CYP3A4 inhibitor added | Restart at 5 mg, do not exceed 5 mg | Drug interaction supersedes prior dose history |

This framework reflects the pharmacokinetic principle that CNS tolerance to sedative-hypnotics, including DORAs, dissipates over roughly 4 to 8 weeks of abstinence, and that women with higher drug exposure (due to sex-related PK differences described above) have a physiological reason to be more conservative on escalation than the label's permissive "may increase to 10 mg" language implies.

Dose Escalation After Re-Titration: What to Track

Once you restart at 5 mg, keeping a brief sleep diary for the first two weeks gives you and your clinician objective data. Track:

• Time you took the tablet
• Approximate time you fell asleep
• Number of night awakenings
• Final wake time
• Self-rated next-morning alertness on a 1 to 5 scale
• Any unusual events (vivid dreams, sleep paralysis, parasomnias)

A formal tool such as the Insomnia Severity Index (ISI), a validated 7-item questionnaire with a score range of 0 to 28, gives a clinically meaningful baseline. An ISI score above 14 indicates clinically significant insomnia. Reassessing at 2 and 6 weeks after restart lets you and your provider make a data-informed escalation decision rather than a subjective one.

The ISI has been validated in menopausal populations specifically, including in the MsFLASH consortium data, making it particularly apt for perimenopausal and postmenopausal women restarting Dayvigo.

Drug Interactions That Change the Re-Titration Calculation

Several drug-drug interactions are especially relevant for women restarting Dayvigo.

Fluconazole (commonly prescribed for recurrent vulvovaginal candidiasis): a moderate-to-strong CYP3A4 inhibitor that meaningfully increases lemborexant exposure. The FDA label caps the dose at 5 mg during co-administration.

Oral contraceptives: Ethinyl estradiol is a mild CYP3A4 inducer that may slightly reduce lemborexant AUC, though the clinical significance is not established and no dose adjustment is specified. Do not change your contraceptive method on this basis alone.

CNS depressants (benzodiazepines, Z-drugs, opioids, gabapentin, sedating antihistamines): additive CNS depression with lemborexant is a real safety concern. If you are restarting Dayvigo and are also taking any of these, a frank conversation about cumulative sedation risk is necessary before your first re-titration dose.

Alcohol: though not a prescription drug, alcohol is a potent CYP3A4 inhibitor and CNS depressant. The combination with lemborexant is explicitly cautioned against in the prescribing information and is particularly dangerous if you take 10 mg.